The efficiency of ranolazine in combination with basic therapy in treatment of chronic coronary syndrome, chronic obstructive pulmonary disease, and obese patients

Abstract

According to the European Society of Cardiology (ESC) guidelines, ranolazine is included in the list of additional treatments in chronic coronary syndrome (CCS) patients because of its ability to reduce the number of angina attacks, the need for sublingual nitroglycerin use and to increase the tolerance to physical exercises.